All articles tagged with #solid tumors
Researchers engineered CAR-T cells to secrete bifunctional fusion proteins targeting PD-L1 for localized IL-12 delivery, enhancing antitumor activity and safety in solid tumor models by modulating the tumor microenvironment and reducing systemic toxicity.
The FDA has granted accelerated approval for the first cell therapy, Amtagvi or lifileucel, for treating advanced melanoma, marking a significant milestone in cancer treatment. This immunotherapy, developed by Iovance, involves harvesting cancer-fighting immune cells from the patient's own body. In a phase 2 clinical trial, 31% of patients who had exhausted standard care options responded to the therapy, with 42% of responders still showing positive results after 18 months. Researchers believe this approval could pave the way for similar successes in treating other solid tumors.
Scientists from UC San Francisco and Northwestern University have developed a new T-cell therapy, called "Judo T-cell therapy," by inserting a mutation found in cancer cells into CAR-T cells, making them 100 times more potent against solid tumors in mice. The researchers have founded a startup, Moonlight Bio, to continue development of this therapy, with lung cancer as their first target for clinical trials within a few years. While concerns about potential risks remain, the team is optimistic about the potential of this approach and plans to continue refining it.
Chicago-based CTRL Therapeutics has raised $10m to develop a new autologous cell therapy that aims to expand beyond the current scope of cancers treated by existing cell therapies and introduce a less complex process for patients and manufacturers. The company is building on another next-generation cell therapy method known as tumor infiltrating lymphocyte, or TIL, therapy, which requires surgically removing cells from the patient’s tumor.